Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer [Yahoo! Finance]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Yahoo! Finance
PR Newswire Tue, February 18, 2025 at 1:00 PM GMT+1 5 min read Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO and CALGARY, AB Feb. 18, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. ( NASDAQ ONCY TSX ONC ), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy pelareorep : the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology ( ASCO ) Gastrointestinal Cancers Symposium in late January. Oncolytics Biotech® Inc. Logo (
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards [Canadian Business Journal (Canada)]Canadian Business Journal
- Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval StandardsGlobeNewswire
- Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal CancerBusiness Wire
- THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis [Canadian Business Journal (Canada)]Canadian Business Journal
- THE VISIBILITY INDEX: 5 Companies Solving the Invisible CrisisGlobeNewswire
ONCY
Earnings
- 11/12/25 - Miss
ONCY
Sec Filings
- 12/16/25 - Form 6-K
- 12/10/25 - Form EFFECT
- 12/10/25 - Form 6-K
- ONCY's page on the SEC website